
NovaBridge Biosciences (NBP) Stock Forecast & Price Target
NovaBridge Biosciences (NBP) Analyst Ratings
Bulls say
NovaBridge Biosciences is well-positioned for success in the biotechnology industry, with a strong immuno-oncology pipeline and a potential best-in-class drug in givastomig. The recent updates on givastomig and VIS-101 demonstrate the company's commitment to building a diverse portfolio with depth and optionality. The company's focus on the US market and strong clinical data further bolster confidence in the potential of NovaBridge's assets and its financial outlook.
Bears say
NovaBridge Biosciences is facing numerous questions and uncertainties regarding the efficacy and market potential of their clinical stage programs, including the durability and tolerability of VIS-101 and the implementation of biomarker-focused patient selection for givastomig. Furthermore, the company's high expenses, primarily driven by acquisitions, and limited cash reserves raise concerns about their ability to support operations beyond 2028. The company also plans to engage in additional research and data analysis, which could further strain their financials.
This aggregate rating is based on analysts' research of NovaBridge Biosciences and is not a guaranteed prediction by Public.com or investment advice.
NovaBridge Biosciences (NBP) Analyst Forecast & Price Prediction
Start investing in NovaBridge Biosciences (NBP)
Order type
Buy in
Order amount
Est. shares
0 shares